

Alcon Announces Launch of SYSTANE® COMPLETE Preservative-Free Lubricant Eye Drops in Canada



- Clinically proven to give instant and all-day* dry eye relief with a single drop, SYSTANE® COMPLETE is now preservative-free
- SYSTANE® COMPLETE Preservative-Free is now widely available starting August 15, 2022

TORONTO, August 15, 2022 /CNW/ – Today Alcon, the global leader in eye care, announced the Canadian launch of the newest addition to its innovative portfolio of dry eye products. New SYSTANE® COMPLETE Preservative-Free Lubricant Eye Drops is an all-in-one solution available in an easy-to-use, multi-dose bottle.

The SYSTANE® COMPLETE Preservative-Free formula works for all types of dry eye, hydrating and protecting with one drop.^{[i] [ii] [iii] [iv]} Alcon’s proprietary, nano-droplet technology allows for fast-acting hydration, tear evaporation protection, and long-lasting relief for a patient’s eyes.³

“We’re thrilled to introduce SYSTANE® COMPLETE Preservative-Free to the Canadian market,” said Chris Gruhn, General Manager of Alcon Canada. “Research shows that 86 percent of dry eye sufferers have some form of evaporative dry eye^[v] yet most eye drops are not designed to address it^[vi]. For those with dry eye symptoms but unclear on what type of dry eye they have, SYSTANE® COMPLETE Preservative-Free can help as it has been clinically demonstrated to provide all day* symptom relief for all types of dry eye, hydrating and protecting with one drop.”¹

Moreover, in a long-term clinical trial, dry eye patients using SYSTANE® COMPLETE four times daily for 6 months† experienced a statistically and clinically significant improvement in symptom scores. Additionally, 20 percent of patients treated with SYSTANE® COMPLETE no longer met the criteria‡ that optometrists use to diagnose dry eye.^[vii]

“Due to increased amounts of screen time, many patients are experiencing dry eye,” said Dr. Eric DesGroseilliers, optometrist at eyeDOCS Ottawa. “I’m happy to recommend SYSTANE® COMPLETE Preservative-Free as an all-in-one solution for Canadians’ dry eye symptoms.”

SYSTANE® COMPLETE Preservative-Free will be available nationally in optometry practices, optical retailers, online and national retailers.

For more information, visit Systane.ca.

* 8 hours

† Signs and symptoms of dry eye were evaluated in a prospective, long-term, double-masked, parallel group, randomized controlled trial for patients with dry eye disease. Patients instilled SYSTANE® COMPLETE four times daily for 6 months (n=99).

‡ According to OSDI (Ocular surface disease index), DEQ-5 (Dry eye questionnaire 5=item), and SANDE (Symptom assessment in dry eye), $p \leq 0.01$.

Refer to product instructions for complete wear, care and safety information on SYSTANE® products.



-30-

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca. You can also connect with us on [Instagram](#) and [Facebook](#).

SOURCE Alcon Canada

For further information:

Max Mosher

max.mosher@edelman.com

+1 (647) 245-7754

References

[i] Silverstein S, Yeu E, Tauber J. et al. Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV. Multicenter Trial. Clin Ophthalmol. 2020;14:3167-3177.m.

[ii] Consumer Eye Drop Research, Global Path-To-Purchase; Alcon data on file, 2017.

[iii] Ketelson H, Rangarajan R. Pre-clinical evaluation of a novel phospholipid nanoemulsion based lubricant eye drops. Poster presented at ARVO 2017, Baltimore, MD.

[iv] Rangarajan R, Ketelson H. Preclinical evaluation of a new hydroxypropyl-guar phospholipid nanoemulsion-based artificial tear formulation in models of corneal epithelium. *J Ocul Pharmacol Ther.* 2019;35(1):32-37.

[v] Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea.* 2012;31:472–478.

[vi] Alcon data on file, 2021.

[vii] Craig JP, et al. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. *Ocul Surf.* 2021;20:62-69.